JW Pharmaceutical Corp Net Assets

Latest as of June 2026: ₩409.94 Billion KRW ≈ $277.81 Million USD

JW Pharmaceutical Corp net assets. Based on the latest financial reports, JW Pharmaceutical Corp (001065) has net assets worth ₩409.94 Billion KRW (≈ $277.81 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩659.89 Billion ≈ $447.20 Million USD) and total liabilities (₩249.96 Billion ≈ $169.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is JW Pharmaceutical Corp growing its equity to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩409.94 Billion
% of Total Assets	62.12%
Annual Growth Rate	4.82%
5-Year Change	95.91%
10-Year Change	33.68%
Growth Volatility	13.23

Net Assets of JW Pharmaceutical Corp (2014–2025)

Net assets of JW Pharmaceutical Corp from 2014 to 2025. This chart illustrates how JW Pharmaceutical Corp's net assets have evolved over time, based on quarterly financial data. See 001065 equity financing ratio to measure how much of total assets are equity-financed.

Annual Net Assets for JW Pharmaceutical Corp (2014–2025)

The table below shows the annual net assets of JW Pharmaceutical Corp from 2014 to 2025. For live market cap and overall valuation, see 001065 stock market capitalisation.

Year	Net Assets	Change
2025-12-31	₩369.37 Billion ≈ $250.32 Million	+12.10%
2024-12-31	₩329.49 Billion ≈ $223.29 Million	+24.13%
2023-12-31	₩265.44 Billion ≈ $179.89 Million	+17.58%
2022-12-31	₩225.76 Billion ≈ $152.99 Million	+19.74%
2021-12-31	₩188.54 Billion ≈ $127.77 Million	-9.12%
2020-12-31	₩207.47 Billion ≈ $140.60 Million	-9.83%
2019-12-31	₩230.09 Billion ≈ $155.93 Million	-11.54%
2018-12-31	₩260.11 Billion ≈ $176.27 Million	-3.94%
2017-12-31	₩270.78 Billion ≈ $183.50 Million	-2.00%
2016-12-31	₩276.31 Billion ≈ $187.25 Million	+22.58%
2015-12-31	₩225.41 Billion ≈ $152.75 Million	+2.45%
2014-12-31	₩220.02 Billion ≈ $149.11 Million	--

Equity Component Analysis

This analysis shows how different components contribute to JW Pharmaceutical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 292.9% over the analyzed period, indicating profitable operations and earnings retention.

JW Pharmaceutical Corp Net Assets Breakdown (December 2025)

JW Pharmaceutical Corp net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Retained Earnings	₩214.57 Billion	58.09%
Other Components	₩154.80 Billion	41.91%
Total Equity	₩369.37 Billion	100.00%

JW Pharmaceutical Corp Competitors by Market Cap

The table below lists competitors of JW Pharmaceutical Corp ranked by their market capitalization.

Company	Market Cap
Jiangsu Yuxing Film Tech SHE:300305	$278.51 Million
Accent Group Ltd AU:AX1	$278.62 Million
Laser Tek Taiwan Co Ltd TWO:6207	$278.65 Million
J.Jill Inc NYSE:JILL	$278.69 Million
Ratnaveer Precision Engineering Ltd NSE:RATNAVEER	$278.48 Million
Eastern Pioneer Auto Driving S SHG:603377	$278.47 Million
Wuhan Hanshang Group Co Ltd SHG:600774	$278.46 Million
Cotec Construction JSC VN:CTD	$278.28 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in JW Pharmaceutical Corp's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 329,486,740,930 to 369,369,598,680, a change of 39,882,857,750 (12.1%).
Net income of 61,511,192,810 contributed positively to equity growth.
Dividend payments of 11,068,208,750 reduced retained earnings.
Share repurchases of 9,539,885,050 reduced equity.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩61.51 Billion	+16.65%
Dividends Paid	₩11.07 Billion	-3.0%
Share Repurchases	₩9.54 Billion	-2.58%
Other Changes	₩-1.02 Billion	-0.28%
Total Change	₩-	12.10%

Book Value vs Market Value Analysis

This analysis compares JW Pharmaceutical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.25x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 1.56x to 1.25x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩13077.48	₩20450.00	x
2018-12-31	₩12533.97	₩20450.00	x
2019-12-31	₩11131.31	₩20450.00	x
2020-12-31	₩10041.95	₩20450.00	x
2021-12-31	₩9182.78	₩20450.00	x
2022-12-31	₩10656.13	₩20450.00	x
2023-12-31	₩11440.15	₩20450.00	x
2024-12-31	₩14205.66	₩20450.00	x
2025-12-31	₩16380.38	₩20450.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently JW Pharmaceutical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 16.65%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.93%
• Asset Turnover: 1.28x
• Equity Multiplier: 1.64x
Recent ROE (16.65%) is above the historical average (3.62%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-1.09%	-0.57%	0.70x	2.73x	₩-23.97 Billion
2015	0.87%	0.45%	0.71x	2.73x	₩-20.52 Billion
2016	-3.96%	-2.34%	0.72x	2.36x	₩-38.56 Billion
2017	-0.27%	-0.15%	0.80x	2.33x	₩-27.82 Billion
2018	3.10%	1.50%	0.90x	2.28x	₩-17.95 Billion
2019	-10.99%	-4.94%	0.89x	2.49x	₩-48.28 Billion
2020	-7.35%	-2.78%	1.00x	2.65x	₩-35.99 Billion
2021	-0.48%	-0.16%	0.96x	3.15x	₩-21.09 Billion
2022	13.27%	4.66%	1.09x	2.61x	₩7.86 Billion
2023	13.94%	4.94%	1.16x	2.43x	₩10.46 Billion
2024	19.74%	9.04%	1.19x	1.83x	₩32.09 Billion
2025	16.65%	7.93%	1.28x	1.64x	₩24.57 Billion

Industry Comparison

This section compares JW Pharmaceutical Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $490,498,627,337
Average return on equity (ROE) among peers: 5.97%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
JW Pharmaceutical Corp (001065)	₩409.94 Billion	-1.09%	0.61x	$278.50 Million
Dongwha Pharm.Co.Ltd (000020)	$229.62 Billion	7.70%	0.48x	$98.05 Million
Yuhan Corp. (000100)	$1.12 Trillion	8.27%	0.18x	$3.84 Billion
Yuhan Corp Preferred (000105)	$2.36 Trillion	8.22%	0.36x	$45.29 Million
Yuyu Pharma (000220)	$82.83 Billion	5.48%	0.47x	$40.03 Million
Yuyu Pharma Inc (000225)	$78.29 Billion	7.52%	0.42x	$13.08 Million
Yuyu Pharma Inc (000227)	$78.29 Billion	7.52%	0.42x	$32.56 Million
Ildong Holdings Co Ltd (000230)	$349.98 Billion	5.99%	1.02x	$43.17 Million
Samil Pharm (000520)	$70.03 Billion	11.32%	0.65x	$108.19 Million
Donga Socio Holdings (000640)	$306.84 Billion	8.70%	1.30x	$379.59 Million
Jw Pharmac (001060)	$230.09 Billion	-10.98%	1.49x	$349.95 Million

About JW Pharmaceutical Corp

KO:001065 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$278.50 Million

₩410.96 Billion KRW

Market Cap Rank

#14890 Global

#477 in Korea

Share Price

₩20450.00

Change (1 day)

-2.15%

52-Week Range

₩19800.00 - ₩29850.00

All Time High

₩88605.96